Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Lumito

0,02 SEK

Mindre end 1K følgere

LUMITO

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+6,67 %
+14,29 %
0,00 %
-69,23 %
-91,12 %
-90,88 %
-96,99 %
-99,05 %
-96,72 %

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Læs mere
Markedsværdi
27,53 mio. SEK
Aktieomsætning
-
Omsætning
100 t
EBIT %
-38.300 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning t

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
20.2
2026

Årsrapport '25

7.5
2026

Generalforsamling '26

7.5
2026

Delårsrapport Q1'26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelsefor 23 timer siden

Lumito receives patent approval in India

Lumito
Selskabsmeddelelse28.1.2026, 07.30

Two Swedish research customers place orders for Lumito’s SCIZYS Erbium Kit

Lumito
Selskabsmeddelelse23.1.2026, 13.50

Lumito’s technology presented at The Pathological Society of Great Britain & Ireland Winter Meeting 2026

Lumito

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse20.1.2026, 15.30

Changes to the Nomination Committee ahead of Lumito’s Annual General Meeting 2026

Lumito
Selskabsmeddelelse13.1.2026, 08.30

Analyst Group initiates coverage of Lumito

Lumito
Selskabsmeddelelse12.1.2026, 08.15

Lumito receives order from Swedish research unit

Lumito
Selskabsmeddelelse8.1.2026, 12.00

Lumito publishes investor letter – 2025 in review and the road ahead

Lumito
Selskabsmeddelelse19.12.2025, 14.00

The Board of Directors of Lumito proposes a reversed share split

Lumito
Selskabsmeddelelse18.12.2025, 11.15

Lumito’s technology enables quantification of low abundant cells

Lumito
Selskabsmeddelelse12.12.2025, 08.00

Lumito strengthens its international presence and participates in Digital Pathology & AI Congress Europe

Lumito
Selskabsmeddelelse11.12.2025, 09.30

Lumito renews its quality certification, ISO 13485:2016

Lumito
Selskabsmeddelelse5.12.2025, 13.15

Nomination Committee for Lumito appointed ahead of the 2026 Annual General Meeting

Lumito
Selskabsmeddelelse2.12.2025, 07.30

Lumito Appoints Chief Business Officer to accelerate commercial growth

Lumito
Selskabsmeddelelse27.11.2025, 07.30

Lumito AB publishes interim report for the third quarter of 2025

Lumito
Selskabsmeddelelse25.11.2025, 09.00

Invitation to webinar in connection with Lumito AB’s Q3 2025 Interim Report

Lumito
Selskabsmeddelelse21.11.2025, 08.45

Lumito granted SEK 250,000 business development grant from Region Skåne

Lumito
Selskabsmeddelelse19.11.2025, 15.45

Conversion of paid subscribed units (BTUs) and first day of trading in warrants of series TO7

Lumito
Pressemeddelelse19.11.2025, 06.47

BioStock: Video from Lumito's presentation at BioStock Life Science Summit 2025

Lumito
Selskabsmeddelelse11.11.2025, 21.30

Lumito's Board of Directors resolves on a directed share issue of units to guarantors in connection with the completed rights issue

Lumito
Selskabsmeddelelse3.11.2025, 18.10

Lumito announces outcome in rights issue

Lumito
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.